The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept

By A. Szallasi, D. Cortright, Charles A. Blum, S. R. Eid. Nature reviews. Drug discovery, 2007

860 citations recorded by the source corpus.

Subfields: Complementary and alternative medicine, Physiology, Sensory Systems

View Paper: https://www.semanticscholar.org/paper/bc5b90cbd297cb438253e5d471bf57d9ae288813

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Complementary and alternative medicine

1. Clifford J. Woolf

In Physiology

1. R. Baron
2. Clifford J. Woolf
3. Christian A. von Hehn
4. Jie Zheng
5. Ardem Patapoutian
6. M. Trudeau
7. R. Ji
8. Arne May

In Sensory Systems

1. Clifford J. Woolf
2. Ardem Patapoutian
3. Jie Zheng
4. Christian A. von Hehn
5. S. Tate
6. R. Baron
7. M. Trudeau
8. D. Julius

Citations in the corpus

• Handbook of ion channels (2015, background): “In fact, selective TRPV1 antagonists were developed by multiple groups quite quickly, and within 10 years of the cloning of the gene, clinical candidate compounds were undergoing trials in humans (160).”
• Deconstructing the Neuropathic Pain Phenotype to Reveal Neural Mechanisms (2012, positive): “These complications may be addressed by targeting specific activation sites independent of temperature activation (Szallasi et al., 2007; Watabiki et al., 2011).”
• Transient receptor potential channels: targeting pain at the source (2009, background): “Similarly, many TRPV1 antagonists seem to reduce mechanical nociception, whereas Trpv1 −/− mice have normal mechanical responses (reviewed in Ref”